OBJECTIVE: Positron emission tomography (PET) is now primarily used in oncological indication owing to the successful application of fluorine-18 fluorodeoxyglucose (FDG) in an increasing number of clinical indications. Glucose transporter 1 (GLUT-1) is recognized as a major early marker of cellular malignant transformation. The aims of this study were to assess whether FDG-PET is a useful diagnostic tool for renal cell carcinoma and to compare the pathologic characteristics. METHODS: Nineteen consecutive patients who had renal cell carcinoma were examined using FDG-PET preoperatively. The results of PET were then compared to the histology obtained after radical surgery and the immunoreactivity of GLUT-1 was also studied. RESULTS: Pathologic examination confirmed that all 19 patients suffered from renal cell carcinoma. Increased FDG uptake was found in six of the 19 patients (31.5%). The immunohistochemical examination of GLUT-1 in renal cell carcinoma produced different results in each patient. There was no correlation with GLUT-1 immunoreactivity and FDG-PET positivity. CONCLUSION: These results suggest that FDG-PET may not be a useful diagnostic tool for renal cell carcinoma.
OBJECTIVE: Positron emission tomography (PET) is now primarily used in oncological indication owing to the successful application of fluorine-18 fluorodeoxyglucose (FDG) in an increasing number of clinical indications. Glucose transporter 1 (GLUT-1) is recognized as a major early marker of cellular malignant transformation. The aims of this study were to assess whether FDG-PET is a useful diagnostic tool for renal cell carcinoma and to compare the pathologic characteristics. METHODS: Nineteen consecutive patients who had renal cell carcinoma were examined using FDG-PET preoperatively. The results of PET were then compared to the histology obtained after radical surgery and the immunoreactivity of GLUT-1 was also studied. RESULTS: Pathologic examination confirmed that all 19 patients suffered from renal cell carcinoma. Increased FDG uptake was found in six of the 19 patients (31.5%). The immunohistochemical examination of GLUT-1 in renal cell carcinoma produced different results in each patient. There was no correlation with GLUT-1 immunoreactivity and FDG-PET positivity. CONCLUSION: These results suggest that FDG-PET may not be a useful diagnostic tool for renal cell carcinoma.
Authors: Samira A Brooks; Amir H Khandani; Julia R Fielding; Weili Lin; Tiffany Sills; Yueh Lee; Alexandra Arreola; Mathew I Milowsky; Eric M Wallen; Michael E Woods; Angie B Smith; Mathew E Nielsen; Joel S Parker; David S Lalush; W Kimryn Rathmell Journal: Clin Cancer Res Date: 2016-01-19 Impact factor: 12.531
Authors: Daniel R Crooks; Nunziata Maio; Martin Lang; Christopher J Ricketts; Cathy D Vocke; Sandeep Gurram; Sevilay Turan; Yun-Young Kim; G Mariah Cawthon; Ferri Sohelian; Natalia De Val; Ruth M Pfeiffer; Parthav Jailwala; Mayank Tandon; Bao Tran; Teresa W-M Fan; Andrew N Lane; Thomas Ried; Darawalee Wangsa; Ashkan A Malayeri; Maria J Merino; Youfeng Yang; Jordan L Meier; Mark W Ball; Tracey A Rouault; Ramaprasad Srinivasan; W Marston Linehan Journal: Sci Signal Date: 2021-01-05 Impact factor: 8.192
Authors: Astrid A M van der Veldt; Martijn R Meijerink; Alfons J M van den Eertwegh; Epie Boven Journal: Target Oncol Date: 2010-07-14 Impact factor: 4.493